Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial

BACKGROUND. For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 00...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Oizumi, Satoshi, Kobayashi, Kunihiko, Inoue, Akira, Maemondo, Makoto, Sugawara, Shunichi, Yoshizawa, Hirohisa, Isobe, Hiroshi, Harada, Masao, Kinoshita, Ichiro, Okinaga, Shoji, Kato, Terufumi, Harada, Toshiyuki, Gemma, Akihiko, Saijo, Yasuo, Yokomizo, Yuki, Morita, Satoshi, Hagiwara, Koichi, Nukiwa, Toshihiro
Формат: Artigo
Язык:Inglês
Опубликовано: AlphaMed Press 2012
Предметы:
Lung Cancer
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3380886/
https://ncbi.nlm.nih.gov/pubmed/22581822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0426
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы